blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4003959

EP4003959 - TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  23.02.2024
Database last updated on 14.11.2024
FormerExamination is in progress
Status updated on  23.06.2023
FormerRequest for examination was made
Status updated on  29.04.2022
FormerThe international publication has been made
Status updated on  29.01.2021
Formerunknown
Status updated on  31.07.2020
Most recent event   Tooltip23.02.2024Application deemed to be withdrawnpublished on 27.03.2024  [2024/13]
Applicant(s)For all designated states
Bayer AS
Drammensveien 288
0283 Oslo / NO
For all designated states
Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
51373 Leverkusen / DE
[2022/22]
Inventor(s)01 / BÖHNKE, Niels
Sächsische Str. 41
10713 Berlin / DE
02 / ZITZMANN-KOLBE, Sabine
Seppenrader Weg 15
13507 Berlin / DE
03 / HAMMER, Stefanie
Neue Welt 12
10247 Berlin / DE
04 / WITTROCK, Sven
Schumannstraße 9
10117 Berlin / DE
05 / BIERER, Donald
Horst 9
42781 Haan / DE
06 / POETHKO, Thorsten
Gustavstrasse 5
58332 Schwelm / DE
07 / BRIEM, Hans
Baumhauser Weg 41a
28279 Bremen / DE
08 / STEUBER, Holger, Magnus
Rabenstrasse 29
13505 Berlin / DE
09 / SCHÄFER, Martina
Gurnemanzpfad 77
13465 Berlin / DE
10 / MEIER, Robin, Michael
Gutenzeller Str. 52
88489 Wain / DE
11 / CELIK, Arif
Heiligenseestraße 10
13503 Berlin / DE
12 / PREUSSE, Cornelia
Heidenheimer Str. 28a
13467 Berlin / DE
13 / ROTTMANN, Antje
Schneehornpfad 11A
13089 Berlin / DE
14 / WERBECK, Nicolas
Paul-Robeson-Str. 8 II
10439 Berlin / DE
15 / KRISTIAN, Alexander
Herman Foss gate 20B
0171 Oslo / NO
16 / INDREVOLL, Bård
Hasleveien 41
0575 Oslo / NO
17 / CUTHBERTSON, Alan
Orrevein 14
0789 Oslo / NO
18 / PAPPLE, Alex
Toverudveien 306
1930 Aurskog / NO
 [2022/22]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[2022/22]
Application number, filing date20744039.724.07.2020
[2022/22]
WO2020EP70922
Priority number, dateEP2019018823125.07.2019         Original published format: EP 19188231
[2022/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021013978
Date:28.01.2021
Language:EN
[2021/04]
Type: A1 Application with search report 
No.:EP4003959
Date:01.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 28.01.2021 takes the place of the publication of the European patent application.
[2022/22]
Search report(s)International search report - published on:EP28.01.2021
ClassificationIPC:C07D213/81, A61K51/04, A61P35/00
[2022/22]
CPC:
C07D213/81 (EP); A61K51/1096 (US); A61K45/06 (US);
A61K51/0402 (EP); A61K51/0478 (US); A61K51/0497 (EP,US);
A61K51/065 (US); A61K9/0019 (US); A61P35/00 (US);
C07B2200/05 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/22]
TitleGerman:ZIELGERICHTETE RADIOPHARMAZEUTIKA ZUR DIAGNOSE UND BEHANDLUNG VON PROSTATAKREBS[2022/22]
English:TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER[2022/22]
French:PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE[2022/22]
Entry into regional phase25.02.2022National basic fee paid 
25.02.2022Designation fee(s) paid 
25.02.2022Examination fee paid 
Examination procedure25.02.2022Examination requested  [2022/22]
25.02.2022Date on which the examining division has become responsible
25.08.2022Amendment by applicant (claims and/or description)
27.06.2023Despatch of a communication from the examining division (Time limit: M04)
08.11.2023Application deemed to be withdrawn, date of legal effect  [2024/13]
28.11.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/13]
Fees paidRenewal fee
28.06.2022Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.07.202304   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]US5624901  (RAYMOND KENNETH N [US], et al) [A] 1-21* example -; claim - *;
 [AD]WO2013167754  (ALGETA ASA [NO]) [AD] 1-21 * page 32 Formula VI;; example -; claim - *;
 [AD]WO2017211809  (BAYER PHARMA AG [DE], et al) [AD] 1-21 * example -; claim - *
by applicantUS3966781
 WO0160417
 WO0205859
 WO2004091668
 WO2011098611
 WO2012112363
 WO2013022797
 WO2013167754
 WO2013167755
 WO2013167756
 WO2015055318
 WO2016096843
 WO2017211809
    - FEINENDEGEN et al., Radiat Res, (19970000), vol. 148, pages 195 - 201
    - WILBUR, Antibody Immunocon Radiopharm, (19910000), vol. 4, pages 85 - 96
    - K. MATOISHI et al., Chem. Commun., (20000000), pages 1519 - 1520
    - BANKS PRPAQUETTE DM., Bioconjug Chem, (19950000), vol. 6, pages 447 - 458
    - DUBEY IPRATVIEL GMEUNIER B, Journal: Bioconjug Chem, (19980000), vol. 9, pages 627 - 632
    - D. J. KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, page 79
    - "Isotopic Compositions of the Elements 1997", Pure Appl. Chem., (19980000), vol. 70, no. 1, pages 217 - 235
    - H. J. LEIS et al., Curr. Org. Chem., (19980000), vol. 2, page 131
    - ESAKI et al., Tetrahedron, (20060000), vol. 62, page 10954
    - ESAKI et al., Chem. Eur. J., (20070000), vol. 13, page 4052
    - J. R. MORANDI et al., J. Org. Chem., (19690000), vol. 34, no. 6, page 1889
    - N. H. KHAN, J. Am. Chem. Soc., (19520000), vol. 74, no. 12, page 3018
    - S. CHANDRASEKHAR et al., Tetrahedron Letters, (20110000), vol. 52, page 3865
    - HANZLIK et al., J. Org. Chem., (19900000), vol. 55, pages 3992 - 3997
    - R. P. HANZLIK et al., Biochem. Biophys. Res. Commun., (19890000), vol. 160, page 844
    - P. J. REIDER et al., J. Org. Chem., (19870000), vol. 52, pages 3326 - 3334
    - M. JARMAN et al., Carcinogenesis, (19950000), vol. 16, no. 4, pages 683 - 688
    - J. ATZRODT et al., Angew. Chem., Int. Ed., (20070000), vol. 46, page 7744
    - C. L. PERRIN et al., J. Am. Chem. Soc., (20070000), vol. 129, page 4490
    - A. STREITWIESER et al., J. Am. Chem. Soc., (19630000), vol. 85, page 2759
    - C. L. PERRIN et al., J. Am. Chem. Soc., (20050000), vol. 127, page 9641
    - C. L. PERRIN et al., J. Am. Chem. Soc., (20030000), vol. 125, page 15008
    - C. L. PERRIN, Advances in Physical Organic Chemistry, vol. 44, page 144
    - B. TESTA et al., Int. J. Pharm., (19840000), vol. 19, no. 3, page 271
    - A. E. MUTLIB et al., "Efavirenz", Toxicol. Appl. Pharmacol., (20000000), vol. 169, doi:10.1006/taap.2000.9055, page 102, XP001083816

DOI:   http://dx.doi.org/10.1006/taap.2000.9055
    - A. M. SHARMA et al., "Nevirapine", Chem. Res. Toxicol., (20130000), vol. 26, doi:10.1021/tx3004938, page 410, XP055708688

DOI:   http://dx.doi.org/10.1021/tx3004938
    - C. J. WENTHUR et al., J. Med. Chem., (20130000), vol. 56, page 5208
    - F. SCHNEIDER et al., "Rofecoxib", Arzneim. Forsch. / Drug. Res., (20060000), vol. 56, page 295, XP001206685
    - F. MALTAIS et al., "Telaprevir", J. Med. Chem., (20090000), vol. 52, doi:10.1021/jm901023f, page 7993, XP055054210

DOI:   http://dx.doi.org/10.1021/jm901023f
    - "IUPAC Rules Section E", Pure Appl Chem, (19760000), vol. 45, pages 11 - 30
    - S. M. BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - AIELLO et al., New Engl. J. Med., (19940000), vol. 331, page 1480
    - PEER et al., Lab. Invest., (19950000), vol. 72, page 638
    - LOPEZ et al., Invest. Opththalmol. Vis. Sci., (19960000), vol. 37, page 855
    - R. RAMON et al., ChemBioChem, (20110000), vol. 12, pages 625 - 632
    - D. A. EVANS et al., J. Am. Chem. Soc., (19870000), vol. 22, page 6881
    - "Database", Database accession no. 605005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.